Beam Therapeutics reported promising Phase 1/2 data for BEAM-302, demonstrating durable gene correction for AATD. See why I ...

While initial study results suggest Beam's technology can correct alpha-1 antitrypsin deficiency's genetic roots, shares fell ...

Boston biotech Beam Therapeutics has announced initial data from a phase 1/2 trial of its gene therapy for a genetic lung and liver disease, with no serious adverse events reported among the nine ...

The Kennedy College of Science, Department of Physics, invites you to a Doctoral Dissertation defense by Toby Morris titled, "Novel Methods for Radiation Therapy: Theranostic Nanoparticles and FLASH ...

A Beam Therapeutics gene-editing therapy designed to fix a mutation at the root of a rare liver protein deficiency now has early signs of efficacy along with safety data that ease some concerns ...

Crispr Therapeutics (CRSP), and Sarepta Therapeutics (SRPT) shares are lower in relation to a gene therapy death ...

Dr. Musunuru is a co-founder and equity holder of Verve Therapeutics, a gene therapy company, and receives funding from Beam Therapeutics for research, but not for this study. Dr. Richard P.

If you have a history of trauma, you may experience vivid memories of traumatic events long after they've stopped happening. According to PTSD United, about 20% of individuals who have experienced ...

BEAM-302 "has set the bar for efficacy in this space," William Blair analysts wrote in an investor note on Monday.

Cargo was founded by two highly acclaimed cell-therapy researchers. The company raised over $500 million to develop ...

The godmother of a young teenager, who is fighting a rare form of cancer, has set up a fundraising appeal to help him and his family.